Successful therapy of Clostridium difficile infection with fecal microbiota transplantation

Journal of Physiology and Pharmacology

Volumn 67, Issue 6, 2016, Pages 859-866

  Konturek, P C ^a   Koziel, J ^b   Dieterich, W ^c   Haziri, D ^a   Wirtz, S ^c   Glowczyk, I ^b   Konturek, K ^a   Neurath, M F ^c   Zopf, Y ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

C reactive protein; Clostridum difficile infection; Fecal calprotectin; Fecal microbiota therapy; Fluorescence activated cell sorting; Gut microbiota; Interleukin 12; Interleukin 1 ; Interleukin 6; Interleukin 8; LL 37; Tumor necrosis factor alpha

Indexed keywords

BACTERIAL RNA; C REACTIVE PROTEIN; CALGRANULIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; RNA 16S; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT;

ABDOMINAL DISCOMFORT; ACIDAMINOCOCCACEAE; AGED; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLONOSCOPY; DEATH; DESULFOVIBRIONACEAE; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; HEALING; HUMAN; INTESTINE ENDOSCOPY; INTESTINE FLORA; LACTOBACILLACEAE; MALE; MICROBIAL DIVERSITY; MICROBIOME; PORPHYROMONADACEAE; RUMINOCOCCACEAE; SUTTERELLACEAE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; INFLAMMATION; METABOLISM; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLONOSCOPY; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85012996416     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sun J, Chang EB. Exploring gut microbes in human health and disease: pushing the envelope. Genes Dis 2014; 1: 132-139.
2. Sommer F, Backhed F. The gut-microbiota-masters of host development and physiology. Nat Rev Microbiol 2013; 11: 227-238.
3. Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol 2015; 66: 483-491.
4. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 2016; 13: 206-216.
5. Magee G, Strauss ME, Thomas SM, Brown H, Baumer D, Broderick KC. Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: a multicenter retrospective study of inpatients, 2009-2011. Am J Infect Control 2015; 43: 1148-1153.
6. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012; 18 (Suppl. 6): 5-12.
7. Ofozu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 2016; 29: 147-154
8. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65: 330-339.
9. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015; 149: 223-237.
10. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-859.
11. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
12. Li YT, Cai HF, Wang ZH, Xu J, Fang JY. Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Alim Pharmacol Ther 2016; 43: 445-457.
13. Fujitani S, George WL, Murthy AR. Comparision of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 32: 220-228.
14. Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu Rev Med 2015; 66: 373-386.
15. Fadrosh DW, Ma B, Gajer P, et al. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome 2014; 2: 6. doi: 10.1186/2049-2618-2-6.
16. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 2013; 10: 996-998.
17. Huson DH, Weber N. Microbial community analysis using MEGAN. Methods Enzymol 2013; 531: 465-485.
18. Song D, Zong X, Zhang H, et al. Antimicrobial peptide cathelicidin-BF prevents intestinal barrier dysfunction in a mouse model of endotoxemia. Int Immunopharmacol 2015; 25: 141-147.
19. Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 2016; 111: 1024-1031.
20. Wang S, Xu M, Wang W, et al. Systematic review: Adverse events of fecal microbiota transplantation. PLoS One 2016; 11: e0161174. doi: 10.1371/journal.pone.0161174
21. Link A, Lachmund T, Schulz C, Weigt J, Malfertheiner P. Endoscopic peroral jejunal fecal microbiota transplantation. Dig Liver Dis 2016; 48: 1336-1339.
22. Kelly CR, Khortus A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016; 165: 609-616.
23. Jeong JJ, Kim KA, Jang SE, Woo JY, Han MJ, Kim DH. Orally administrated Lactobacillus pentosus var. plantarum C29 ameliorates age-dependent colitis by inhibiting the nuclear factor-kappa B signaling pathway via the regulation of lipopolysaccharide production by gut microbiota. PLoS One 2015; 10: e116533. doi: 10.1371/journal.pone.0116533
24. Khanna S, Montassier E, Schmidt B, et al. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Alim Pharmacol Ther 2016; 44: 715-727.
25. Zhang-Sun W, Augusto LA, Zhao L, Caroff M. Desulfovibrio desulfuricans isolates from the gut of a single individual: structural and biological lipid A characterization. FEBS Lett 2015; 589: 165-171.
26. Magierowski M, Jasnos K, Kwiecien S, et al. Endogenous prostaglandins and afferent sensory nerves in gastroprotective effect of hydrogen sulfide against stress-induced gastric lesions. PLoS One 2015; 10: e0118972. doi: 10.1371/journal.pone.0118972
27. Hiippala K, Kainulainen V, Kalliomaki M, Arkilla P. Satokari R. Mucosal prevalence and interactions with the epithelium indicate commensalism of Sutterella spp. Front Microbiol 2016;7: 1706.
28. Schubert AM, Sinani H, Schloss PD. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio 2015; 6: e00974. doi: 10.1128/mBio.00974-15
29. Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014; 306: G310-G319.
30. Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal microbiota transplantation for recurrent Clostridium difficile infection in elderly: long term outcomes and microbiota changes. Dig Dis Sci 2016; 61: 3007-3015.